公开(公告)号：US11814370B2

公开(公告)日：2023-11-14

申请号：US16339056

申请日：2017-10-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Matthew D. Cheeseman ,  A. Elisa Pasqua ,  Michael J. Tucker

IPC: C07D405/12 ,  C07B59/00 ,  A61P35/00

CPC classification number: C07D405/12 ,  C07B59/002 ,  A61P35/00 ,  C07B2200/05

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

公开(公告)号：US11802160B2

公开(公告)日：2023-10-31

申请号：US16782440

申请日：2020-02-05

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US11766434B2

公开(公告)日：2023-09-26

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20230278989A1

公开(公告)日：2023-09-07

申请号：US18159452

申请日：2023-01-25

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Steven HOWARD ,  Benjamin David CONS ,  Jeffrey David ST. DENIS ,  Charlotte Mary GRIFFITHS-JONES ,  Steven Douglas HISCOCK ,  Rhian Sara HOLVEY ,  Alan Richard BURNS ,  David COUSIN ,  Hannah Louise DEXTER ,  Guillaume François PARRA ,  John Paul WATTS ,  Robert JEWELL ,  Jennifer Ann STOCKWELL ,  Kim Louise HIRST ,  Isabelle Anne LEMASSON ,  David John NASH ,  James Daniel OSBORNE ,  Jonas Calleja PRIEDE ,  Nicholas Paul RICHARDS ,  Aaron Michael DUMAS ,  Brian Christopher BISHOP ,  David PARRY-JONES ,  Jeremy Peter SCOTT ,  Meenakshi Sundaram SHANMUGHAM ,  Peter Richard MULLENS ,  David Charles LATHBURY ,  Darren James DIXON ,  Matthew James GAUNT

IPC: C07D405/06

CPC classification number: C07D405/06 ,  C07B2200/13

Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

公开(公告)号：US20230265200A1

公开(公告)日：2023-08-24

申请号：US17706028

申请日：2022-03-28

Applicant: Cancer Research Technology Limited

Inventor： Sergio Quezada ,  Karl Peggs ,  Frederick Arce Vargas

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2866 ,  C07K16/2815 ,  C07K16/2812 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).

公开(公告)号：US11560406B2

公开(公告)日：2023-01-24

申请号：US15918268

申请日：2018-03-12

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Ferdinando Auricchio ,  Antimo Migliaccio

IPC: C07K14/705 ,  C07K7/08 ,  C07K14/72 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06

Abstract: The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m-Y. The peptides are for medical use, in particular as anti-tumoral agents.

公开(公告)号：US11519021B2

公开(公告)日：2022-12-06

申请号：US16327847

申请日：2017-08-23

Applicant: Cancer Research Technology Limited

Inventor： John Burn ,  Mohammed Ghanim Mehdi Alhilal ,  Francisco Mauro Santibanez-Koref ,  Lisa Redford ,  Michael Stewart Jackson

IPC: C12Q1/6827 ,  C12Q1/686 ,  C12Q1/6869

Abstract: The present invention relates to methods and kits for identifying microsatellite instability (MSI) in a sample. In particular it relates to identifying microsatellite instability in a tumor sample, which may be from a subject suspected of having colorectal cancer or Lynch syndrome. The methods and kits can be used to identify mismatch repair defects. More particularly the invention relates to a panel of markers for a sequencing based MSI test, that can differentiate between MSI-H and MSS CRCs. The invention also allows for determination of biological significance, differentiating between PCR and sequencing errors and MSI induced indels/mutations.

公开(公告)号：US20220220476A1

公开(公告)日：2022-07-14

申请号：US17609691

申请日：2020-05-22

Applicant: Cancer Research Technology Limited

Inventor： Monika Gullerova

IPC: C12N15/113

Abstract: The present invention relates to a method of inhibiting expression of a gene in a biological system. The method of the present invention comprises introducing a tRNA-derived polynucleotide into the biological system. The tRNA-derived polynucleotide of the present invention comprises a sequence that is complementary to an intronic region of the gene whose expression is to be inhibited.

公开(公告)号：US20220220097A1

公开(公告)日：2022-07-14

申请号：US17406640

申请日：2021-08-19

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Carl Rye ,  Nicola Chessum ,  Matthew D. Cheeseman ,  Adele E. Pasqua ,  Kurt G. Pike ,  Paul F. Faulder

IPC: C07D405/12 ,  C07D405/14 ,  C07D319/18 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056

Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20220079942A1

公开(公告)日：2022-03-17

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.